Not recruitingISRCTN38354847

A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy

Research studyAges 18–75United KingdomDepression

The study in practice

Understand this study

Listed age limits: 18 years to 75 years.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateNot clearly listed

Recruitment status: Not recruiting
Enrollment listed in the registry: Not clearly listed
Sponsor: Laxdale Ltd (UK)
Sponsor type: Other organization
Study type: Other
Intervention type: Other / unclear
Study phase: Not clearly listed
Locations: United Kingdom
Age range: From 18 Years to 75 Years
Official registry ID: ISRCTN38354847
Official title: Show the full official title
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy

Not recruiting

United Kingdom

FAQ

Who is behind this study?

The study sponsor is Laxdale Ltd (UK).

Who can participate?

Listed age limits: 18 years to 75 years.

Is this study still recruiting?

The registry lists this study as not recruiting.